



LABORATORY DATA CONSULTANTS, INC.

2701 Loker Ave. West, Suite 220, Carlsbad, CA 92010 Bus: 760-827-1100 Fax: 760-827-1099

AECOM
1001 Bishop Street Suite 1600
Honolulu, HI 96813
ATTN: Ms. Alethea Ramos
alethea.ramos@aecom.com

March 1, 2022

SUBJECT: Red Hill Bulk Storage Facility, CTO 18F0126 - Data Validation

Dear Ms. Ramos,

Enclosed are the final validation reports for the fraction listed below. These SDGs were received on October 27, 2021. Attachment 1 is a summary of the samples that were reviewed for the analysis.

LDC Project #52408A:

<u>SDG #</u>	<u>Fraction</u>
B21100806	Total Petroleum Hydrocarbons as Extractables

The data validation was performed under Stage 2B & 4 validation guidelines. The analysis was validated using the following documents and variances, as applicable to the method:

- Work Plan/Scope of Work, Investigation and Remediation of Releases and Groundwater Protection and Evaluation, Red Hill Bulk Fuel Storage Facility, Joint Base Pearl Harbor - Hickam, O'ahu, Hawai'i (Revision 02, January 2017)
- Sampling and Analysis Plan, Investigation and Remediation of Releases and Groundwater Protection and Evaluation, Red Hill Bulk Fuel Storage Facility, Joint Base Pearl Harbor - Hickam, O'ahu, Hawai'i (Revision 01, April 2017)
- Sampling and Analysis Plan, Addendum 01, Investigation and Remediation of Releases and Groundwater Protection and Evaluation, Red Hill Bulk Fuel Storage Facility, Joint Base Pearl Harbor-Hickam, O'ahu, Hawai'i (Revision 00, September 2017)
- Sampling and Analysis Plan, Addendum 03, Investigation and Remediation of Releases and Groundwater Protection and Evaluation, Red Hill Bulk Fuel Storage Facility, Joint Base Pearl Harbor-Hickam, O'ahu, Hawai'i (Revision 00, June 2018)
- U.S. Department of Defense (DoD) Quality Systems Manual (QSM) for Environmental Laboratories, Version 5.3 (2019)
- DoD General Validation Guidelines (November 2019)
- U.S. Department of Defense (DoD) Data Validation Guidelines Module 4: Data Validation Procedure for Organic Analysis by GC (March 2021)
- EPA SW 846, Third Edition, Test Methods for Evaluating Solid Waste, update 1, July 1992; update IIA, August 1993; update II, September 1994; update IIB, January 1995; update III, December 1996; update IIIA, April 1998; IIIB, November 2004; update IV, February 2007; update V, July 2014; update VI, July 2018

Please feel free to contact us if you have any questions.

Sincerely,

Stella Cuenco
Operations Manager/Senior Chemist
scuenco@lab-data.com

90/10 2B/4 EDD

LDC# 52408 (AECOM - Honolulu, HI / Red Hill Bulk Storage Facility, CTO 18F0126)

LDC	SDG#	DATE REC'D	(2) DATE DUE	DRO (8015C)		SGCU DRO (8015C)		W	S	W	S	W	S	W	S	W	S	W	S	W	S	W	S	W	S	W	S	W	S				
				W	S	W	S																										
Matrix: Water/Soil								W	S	W	S	W	S	W	S	W	S	W	S	W	S	W	S	W	S	W	S	W	S	W	S	W	S
A	B21100806	10/27/21	11/01/21	4	0	2	0																										
A	B21100806	10/27/21	11/01/21	3	0	3	0																										
Total	T/SC			7	0	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	12			

Shaded cells indicate Stage 4 validation (all other cells are Stage 2B validation). These sample counts do not include MS/MSD, and DUPs

Laboratory Data Consultants, Inc. Data Validation Report

Project/Site Name: Red Hill Bulk Storage Facility, CTO 18F0126

LDC Report Date: November 9, 2021

Parameters: Total Petroleum Hydrocarbons as Extractables

Validation Level: Stage 2B & 4

Laboratory: Energy Laboratories, Billings, MT

Sample Delivery Group (SDG): B21100806

Sample Identification	Laboratory Sample Identification	Matrix	Collection Date
ERH1784(RHMW01R)	B21100806-001	Water	10/06/21
ERH1787(RHMW02)**	B21100806-002**	Water	10/06/21
ERH1790(RHMW03)**	B21100806-003**	Water	10/06/21
ERH1793(RHMW05)**	B21100806-004**	Water	10/06/21
ERH1796(RHMW2254-01)	B21100806-005	Water	10/06/21
ERH1799(RHSF)	B21100806-006	Water	10/06/21
ERH1801(RHSF)	B21100806-007	Water	10/06/21
ERH1784(RHMW01R)(SGCU)	B21100806-001(SGCU)	Water	10/06/21
ERH1787(RHMW02)(SGCU)**	B21100806-002(SGCU)**	Water	10/06/21
ERH1790(RHMW03)(SGCU)**	B21100806-003(SGCU)**	Water	10/06/21
ERH1793(RHMW05)(SGCU)**	B21100806-004(SGCU)**	Water	10/06/21
ERH1796(RHMW2254-01)(SGCU)	B21100806-005(SGCU)	Water	10/06/21
ERH1784(RHMW01R)MS	B21100806-001MS	Water	10/06/21
ERH1784(RHMW01R)MSD	B21100806-001MSD	Water	10/06/21
ERH1787(RHMW02)MS	B21100806-002MS	Water	10/06/21
ERH1787(RHMW02)MSD	B21100806-002MSD	Water	10/06/21
ERH1784(RHMW01R)(SGCU)MS	B21100806-001(SGCU)MS	Water	10/06/21
ERH1784(RHMW01R)(SGCU)MSD	B21100806-001(SGCU)MSD	Water	10/06/21
ERH1787(RHMW02)(SGCU)MS	B21100806-002(SGCU)MS	Water	10/06/21
ERH1787(RHMW02)(SGCU)MSD	B21100806-002(SGCU)MSD	Water	10/06/21

Samples appended with "SGCU" underwent Silica Gel cleanup
 **Indicates sample underwent Stage 4 validation

Introduction

This Data Validation Report (DVR) presents data validation findings and results for the associated samples listed on the cover page. Data validation was performed in accordance with the Work Plan/Scope of Work, Investigation and Remediation of Releases and Groundwater Protection and Evaluation, Red Hill Bulk Fuel Storage Facility, Joint Base Pearl Harbor-Hickam, O'ahu, Hawai'i (Revision 02, January 2017), the Sampling and Analysis Plan, Investigation and Remediation of Releases and Groundwater Protection and Evaluation, Red Hill Bulk Fuel Storage Facility, Joint Base Pearl Harbor-Hickam, O'ahu, Hawai'i (Revision 01, April 2017), the Sampling and Analysis Plan, Addendum 01, Investigation and Remediation of Releases and Groundwater Protection and Evaluation, Red Hill Bulk Fuel Storage Facility, Joint Base Pearl Harbor-Hickam, O'ahu, Hawai'i (Revision 00, September 2017), the Sampling and Analysis Plan, Addendum 03, Investigation and Remediation of Releases and Groundwater Protection and Evaluation, Red Hill Bulk Fuel Storage Facility, Joint Base Pearl Harbor-Hickam, O'ahu, Hawai'i (Revision 00, June 2018), the U.S. Department of Defense (DoD) Quality Systems Manual (QSM) for Environmental Laboratories, Version 5.3 (2019), the DoD General Validation Guidelines (November 2019), and the U.S. Department of Defense (DoD) Data Validation Guidelines Module 4: Data Validation Procedure for Organic Analysis by GC (March 2021). Where specific guidance was not available, the data has been evaluated in a conservative manner consistent with industry standards using professional experience.

The analyses were performed by the following method:

Total Petroleum Hydrocarbons as Extractables by Environmental Protection Agency (EPA) SW 846 Method 8015C

All sample results were subjected to Stage 2B data validation, which comprises an evaluation of quality control (QC) summary results. Samples appended with a double asterisk on the cover page were subjected to Stage 4 data validation, which is comprised of the QC summary forms as well as the raw data, to confirm sample quantitation and identification.

The following are definitions of the data qualifiers utilized during data validation:

- J+ (Estimated, High Bias): The analyte was analyzed for and positively identified by the laboratory; however the reported concentration is estimated, displaying high bias, due to non-conformances discovered during data validation.
- J- (Estimated, Low Bias): The analyte was analyzed for and positively identified by the laboratory; however the reported concentration is estimated, displaying low bias, due to non-conformances discovered during data validation.
- J (Estimated, Bias Indeterminate): The analyte was analyzed for and positively identified by the laboratory; however the reported concentration is estimated due to non-conformances discovered during data validation. Bias is indeterminate.
- U (Non-detected): The analyte was analyzed for and positively identified by the laboratory; however the analyte should be considered non-detected due to the presence of contaminants detected in the associated blank(s).
- UJ (Non-detected estimated): The analyte was not detected and the associated numerical value is approximate.
- X (Exclusion of data recommended): The sample results (including non-detects) were affected by serious deficiencies in the ability to analyze the sample and to meet published method and project quality control criteria. The presence or absence of the analyte cannot be substantiated by the data provided. Exclusion of the data is recommended.
- NA (Not Applicable): The non-conformance discovered during data validation demonstrates a high bias, while the affected analyte in the associated sample(s) was reported as not detected by the laboratory and did not warrant the qualification of the data.

A qualification summary table is provided at the end of this report if data has been qualified. Flags are classified as P (protocol) or A (advisory) to indicate whether the flag is due to a laboratory deviation from a specified protocol or is of technical advisory nature.

Qualification Code Reference

- a ICP Serial Dilution %D was not within control limits.
- b Presumed contamination from preparation (method blank).
- c Calibration %RSD, r, r², %D or %R was noncompliant.
- d The analysis with this flag should not be used because another more technically sound analysis is available.
- e MS/MSD or Duplicate RPD was high.
- f Presumed contamination from FB or ER.
- g ICP ICS results were unsatisfactory.
- h Holding times were exceeded.
- i Internal standard performance was unsatisfactory.
- k Estimated Maximum Possible Concentration (HRGC/HRMS only)
- l LCS/LCSD %R was not within control limits.
- m Result exceeded the calibration range.
- o Cooler temperature or temperature blank was noncompliant and/or sample custody problems.
- p RPD between two columns was high (GC only).
- q MS/MSD recovery was not within control limits.
- s Surrogate recovery was not within control limits.
- t Presumed contamination from trip blank.
- v Unusual problems found with the data not defined elsewhere. Description of the problem can be found in the validation report.
- w LCS/LCSD RPD was high.
- y Chemical recovery was not within control limits (Radiochemistry only).

I. Sample Receipt and Technical Holding Times

All samples were received in good condition and cooler temperatures upon receipt met validation criteria.

All technical holding time requirements were met.

II. Initial Calibration and Initial Calibration Verification

An initial calibration was performed as required by the method.

The percent relative standard deviations (%RSD) were less than or equal to 20.0% for all analytes.

The percent differences (%D) of the initial calibration verification (ICV) standard were less than or equal to 20.0% for all analytes.

III. Continuing Calibration

Continuing calibration was performed at the required frequencies.

The percent differences (%D) were less than or equal to 20.0% for all analytes.

The percent differences (%D) of the ending continuing calibration verifications (CCVs) were less than or equal to 20.0% for all analytes.

IV. Laboratory Blanks

Laboratory blanks were analyzed as required by the method. No contaminants were found in the laboratory blanks.

V. Field Blanks

No field blanks were identified in this SDG.

VI. Surrogates

Surrogates were added to all samples as required by the method. All surrogate recoveries (%R) were within QC limits with the following exceptions:

Sample	Surrogate	%R (Limits)	Affected Analyte	Flag	A or P
ERH1793(RHMW05)(SGCU)**	Ortho-Terphenyl	55.0 (56-125)	TPH as extractables	UJ (all non-detects)	P

VII. Matrix Spike/Matrix Spike Duplicates

Matrix spike (MS) and matrix spike duplicate (MSD) sample analysis was performed on an associated project sample. Percent recoveries (%R) were within QC limits. Relative percent differences (RPD) were within QC limits.

VIII. Laboratory Control Samples

Laboratory control samples (LCS) were analyzed as required by the method. Percent recoveries (%R) were within QC limits.

IX. Field Duplicates

Samples ERH1799(RHSF) and ERH1801(RHSF) were identified as field duplicates. No results were detected in any of the samples.

X. Target Analyte Quantitation

All target analyte quantitations met validation criteria for samples which underwent Stage 4 validation. Raw data were not reviewed for Stage 2B validation.

XI. Target Analyte Identification

All target analyte identifications met validation criteria for samples which underwent Stage 4 validation. Raw data were not reviewed for Stage 2B validation.

XII. Overall Assessment of Data

The analysis was conducted within all specifications of the method. No results were rejected or recommended for exclusion in this SDG.

Due to surrogate %R, data were qualified as estimated in one sample.

**Red Hill Bulk Storage Facility, CTO 18F0126
 Total Petroleum Hydrocarbons as Extractables - Data Qualification Summary -
 SDG B21100806**

Sample	Analyte	Flag	A or P	Reason (Code)
ERH1793(RHMW05)(SGCU)**	TPH as extractables	UJ (all non-detects)	P	Surrogates (%R) (s)

**Red Hill Bulk Storage Facility, CTO 18F0126
 Total Petroleum Hydrocarbons as Extractables - Laboratory Blank Data
 Qualification Summary - SDG B21100806**

No Sample Data Qualified in this SDG

**Red Hill Bulk Storage Facility, CTO 18F0126
 Total Petroleum Hydrocarbons as Extractables - Field Blank Data Qualification
 Summary - SDG B21100806**

No Sample Data Qualified in this SDG

LDC #: 52408A8

VALIDATION COMPLETENESS WORKSHEET

SDG #: B21100806

Stage 2B/4

Laboratory: Energy Laboratories, Billings, MT

Date: 11/8/21

Page: 1 of 3

Reviewer: [Signature]

2nd Reviewer: [Signature]

METHOD: GC Diesel Range Organics (EPA SW 846 Method 8015C)

TPH Extractables

The samples listed below were reviewed for each of the following validation areas. Validation findings are noted in attached validation findings worksheets.

	Validation Area		Comments
I.	Sample receipt/Technical holding times	A/A	
II.	Initial calibration/ICV	A/A	% PSD / ICV ≤ 20
III.	Continuing calibration ending	Δ	CV ≤ 20/20
IV.	Laboratory Blanks	Δ	
V.	Field blanks	N	
VI.	Surrogate spikes	SW	
VII.	Matrix spike/Matrix spike duplicates	R	
VIII.	Laboratory control samples	A	LC
IX.	Field duplicates	ND	D = 6, 7
X.	Target analyte quantitation	Δ	Not reviewed for Stage 2B validation.
XI.	Target analyte identification	Δ	Not reviewed for Stage 2B validation.
XII.	Overall assessment of data	A	

Note: A = Acceptable
N = Not provided/applicable
SW = See worksheet

ND = No compounds detected
R = Rinsate
FB = Field blank

D = Duplicate
TB = Trip blank
EB = Equipment blank

SB=Source blank
OTHER:

** Indicates sample underwent Stage 4 validation

	Client ID	Lab ID	Matrix	Date
1 ⁺	ERH1784(RHMW01R)	B21100806-001	Water	10/06/21
2 ⁺	ERH1787(RHMW02)**	B21100806-002**	Water	10/06/21
3 ⁺	ERH1790(RHMW03)**	B21100806-003**	Water	10/06/21
4 ⁺	ERH1793(RHMW05)**	B21100806-004**	Water	10/06/21
5 ⁺	ERH1796(RHMW2254-01)	B21100806-005	Water	10/06/21
6 ⁻	ERH1799(RHSF) D	B21100806-006	Water	10/06/21
7 ⁻	ERH1801(RHSF) D	B21100806-007	Water	10/06/21
8 ⁻	ERH1784(RHMW01R)(SGCU)	B21100806-001(SGCU)	Water	10/06/21
9 ⁺	ERH1787(RHMW02)(SGCU)**	B21100806-002(SGCU)**	Water	10/06/21
10 ⁻	ERH1790(RHMW03)(SGCU)**	B21100806-003(SGCU)**	Water	10/06/21
11 ⁻	ERH1793(RHMW05)(SGCU)**	B21100806-004(SGCU)**	Water	10/06/21
12 ⁻	ERH1796(RHMW2254-01)(SGCU)	B21100806-005(SGCU)	Water	10/06/21
13	ERH1784(RHMW01R)MS	B21100806-001MS	Water	10/06/21
14	ERH1784(RHMW01R)MSD	B21100806-001MSD	Water	10/06/21
15	ERH1787(RHMW02)MS	B21100806-002MS	Water	10/06/21
16	ERH1787(RHMW02)MSD	B21100806-002MSD	Water	10/06/21
17	ERH1784(RHMW01R)(SGCU)MS	B21100806-001(SGCU)MS	Water	10/06/21

LDC #: 52408A8

VALIDATION COMPLETENESS WORKSHEET

Date: 11/8/21

SDG #: B21100806

Stage 2B/4

Page: 2 of 2

Laboratory: Energy Laboratories, Billings, MT

Reviewer: [Signature]

2nd Reviewer: [Signature]

METHOD: GC Diesel Range Organics (EPA SW 846 Method 8015C)

	Client ID	Lab ID	Matrix	Date
18	ERH1784(RHMW01R)(SGCU)MSD	B21100806-001(SGCU)MSD	Water	10/06/21
19	ERH1787(RHMW02)(SGCU)MS	B21100806-002(SGCU)MS	Water	10/06/21
20	ERH1787(RHMW02)(SGCU)MSD	B21100806-002(SGCU)MSD	Water	10/06/21
21				
22				
23				

Notes:

160170				

Method: GC HPLC

Validation Area	Yes	No	NA	Findings/Comments
I. Technical holding times				
Were all technical holding times met?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Was cooler temperature criteria met?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Ia. Initial calibration				
Did the laboratory perform a 5 point calibration prior to sample analysis?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Were all percent relative standard deviations (%RSD) \leq 20%?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Was a curve fit used for evaluation? If yes, did the initial calibration meet the curve fit acceptance criteria of \geq 0.990?	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
Were the RT windows properly established?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Iib. Initial calibration verification				
Was an initial calibration verification standard analyzed after each initial calibration for each instrument?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Were all percent differences (%D) \leq 20%?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
III. Continuing calibration				
Was a continuing calibration analyzed daily?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Were all percent differences (%D) \leq 20%?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Were all the retention times within the acceptance windows?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
IV. Laboratory Blanks				
Was a laboratory blank associated with every sample in this SDG?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Was a laboratory blank analyzed for each matrix and concentration?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Was there contamination in the laboratory blanks?	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	
V. Field Blanks				
Were field blanks identified in this SDG?	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	
Were target analytes detected in the field blanks?	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
VI. Surrogate spikes				
Were all surrogate percent recovery (%R) within the QC limits?	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	
If the percent recovery (%R) of one or more surrogates was outside QC limits, was a reanalysis performed to confirm %R?	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	
If any %R was less than 10 percent, was a reanalysis performed to confirm %R?	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
VII. Matrix spike/Matrix spike duplicates				
Were matrix spike (MS) and matrix spike duplicate (MSD) analyzed in this SDG?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Were the MS/MSD percent recoveries (%R) and the relative percent differences (RPD) within the QC limits?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
VIII. Laboratory control samples				
Was an LCS analyzed per analytical or extraction batch?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Were the LCS percent recoveries (%R) and relative percent difference (RPD) within the QC limits?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	

IX. Field duplicates			
Were field duplicate pairs identified in this SDG?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Were target analytes detected in the field duplicates?	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>
X. Target analyte quantitation			
Did the laboratory LOQs/RLs meet the QAPP LOQs/RLs?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Were analyte quantitation and RLs adjusted to reflect all sample dilutions and dry weight factors applicable to level IV validation?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Were manual integrations reviewed and found acceptable?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Did the laboratory provide before and after integration printouts?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
XI. Target analyte identification			
Were the retention times of reported detects within the RT windows?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
XIII. Overall assessment of data			
Overall assessment of data was found to be acceptable.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

LDC #: 52408 AY

VALIDATION FINDINGS WORKSHEET

Surrogate Recovery

Page: 1 of 1
Reviewer: FT

METHOD: GC HPLC

Are surrogates required by the method? Yes or No .

Please see qualifications below for all questions answered "N". Not applicable questions are identified as "N/A".

N N/A Were surrogates spiked into all samples and blanks?

N N/A Did all surrogate recoveries (%R) meet the QC limits? (5)

#	Sample ID	Detector/Column	Surrogate Compound	%R (Limits)	Qualifications
	11		H	55.0 (56-125)	J-431P ND
				()	
				()	
				()	
				()	
				()	
				()	
				()	
				()	
				()	
				()	
				()	
				()	
				()	
				()	
				()	
				()	
				()	
				()	
				()	
				()	
				()	
				()	
				()	
				()	
				()	
				()	

Surrogate Compound		Surrogate Compound		Surrogate Compound		Surrogate Compound			
A	Chlorobenzene (CBZ)	G	Octacosane	M	Benzo(e)Pyrene	S	1-Chloro-3-Nitrobenzene	Y	Tetrachloro-m- xylene
B	4-Bromofluorobenzene (BFB)	H	Ortho-Terphenyl	N	Terphenyl-D14	T	3,4-Dinitrotoluene	Z	2-Bromonaphthalene
C	a,a,a-Trifluorotoluene	I	Fluorobenzene (FBZ)	O	Decachlorobiphenyl (DCB)	U	Tripentyltin	AA	Chloro-octadecane
D	Bromochlorobenene	J	n-Triacontane	P	1-methylnaphthalene	V	Tri-n-propyltin	BB	2,4-Dichlorophenylacetic acid
E	1,4-Dichlorobutane	K	Hexacosane	Q	Dichlorophenyl Acetic Acid (DCAA)	W	Tributyl Phosphate	CC	2,5-Dibromotoluene
F	1,4-Difluorobenzene (DFB)	L	Bromobenzene	R	4-Nitrophenol	X	Triphenyl Phosphate		

LDC #: 52408 AS

VALIDATION FINDINGS WORKSHEET
Initial Calibration Calculation Verification

Page: 1 of 1
Reviewer: FT

METHOD: GC X HPLC _____

The calibration factors (CF), average CF, and relative standard deviation (%RSD) were recalculated for compounds identified below using the following calculations:

CF = A/C
average CF = sum of the CF/number of standards
%RSD = 100 * (S/X)

Where: A = Area of compound
C = Concentration of compound
S = Standard deviation of calibration factors
X = Mean of calibration factors

#	Standard ID	Calibration Date	Compound	Reported 15000ng	Recalculated 15000ng	Reported Average CF (Initial)	Recalculated Average CF (Initial)	Reported %RSD	Recalculated %RSD
1	ICAL	1/8/2021	DRO Range	30201	30201	29457.3	29457.3	5.8	5.8

LDC #: 52408 AY

VALIDATION FINDINGS WORKSHEET
Initial Calibration Calculation Verification

Page: 1 of 1

Reviewer: FT

METHOD: GC X HPLC _____

The calibration factors (CF), average CF, and relative standard deviation (%RSD) were recalculated for compounds identified below using the following calculations:

CF = A/C
average CF = sum of the CF/number of standards
%RSD = 100 * (S/X)

Where: A = Area of compound
C = Concentration of compound
S = Standard deviation of calibration factors
X = Mean of calibration factors

#	Standard ID	Calibration Date	Compound	Reported 5000ng	Recalculated 5000ng	Reported Average CF (Initial)	Recalculated Average CF (Initial)	Reported %RSD	Recalculated %RSD
1	ICAL	2/18/2021	DRO Range	28746	28746	28542.4	28542.4	4.5	4.5

LDC #: 52408178

VALIDATION FINDINGS WORKSHEET
Initial Calibration Calculation Verification

Page: 1 of 1

Reviewer: FT

METHOD: GC X HPLC _____

The calibration factors (CF), average CF, and relative standard deviation (%RSD) were recalculated for compounds identified below using the following calculations:

$CF = A/C$

average CF = sum of the CF/number of standards

$\%RSD = 100 * (S/X)$

Where:

A = Area of compound

C = Concentration of compound

S = Standard deviation of calibration factors

X = Mean of calibration factors

#	Standard ID	Calibration Date	Compound	Reported 15000ng	Recalculated 15000ng	Reported Average CF (Initial)	Recalculated Average CF (Initial)	Reported %RSD	Recalculated %RSD
1	ICAL	12/4/2020	DRO Range	26221.18	26221.18	26029.55	26029.55	2.690	2.690

LDC #: 52408 AX

VALIDATION FINDINGS WORKSHEET
Initial Calibration Calculation Verification

Page: 1 of 1

Reviewer: FT

METHOD: GC X HPLC _____

The calibration factors (CF), average CF, and relative standard deviation (%RSD) were recalculated for compounds identified below using the following calculations:

$CF = A/C$

average CF = sum of the CF/number of standards

$\%RSD = 100 * (S/X)$

Where:

A = Area of compound

C = Concentration of compound

S = Standard deviation of calibration factors

X = Mean of calibration factors

#	Standard ID	Calibration Date	Compound	Reported 15000ng	Recalculated 15000ng	Reported Average CF (Initial)	Recalculated Average CF (Initial)	Reported %RSD	Recalculated %RSD
1	ICAL	10/7/2020	DRO Range	24156.53	24156.53	24529.56	24529.56	2.304	2.304

LDC #: 52408 AB

VALIDATION FINDINGS WORKSHEET
Continuing Calibration Results Verification

Page: 1 of 1
Reviewer: FT

METHOD: GC ✓ HPLC _____

The percent difference (%D) of the initial calibration average Calibration Factors (CF) and the continuing calibration CF were recalculated for the compounds identified below using the following calculation:

% Difference = 100 * (ave. CF - CF)/ave.CF Where: ave. CF = initial calibration average CF
 CF = continuing calibration CF
 A = Area of compound
 C = Concentration of compound

#	Standard ID	Calibration Date	Compound	Average CF(ICAL)/ CCV Conc.	Reported	Recalculated	Reported	Recalculated
					CF/ Conc. CCV	CF/ Conc. CCV	%R	%R
1	CCV 13r 0654	10/11/21	DRG (C10-C24)	15	15	14.725	98	98
2	CCV 26r 0453	10/12/21	↓	15	15	15.464	103	103
3	CCV 41r 1534	10/12/21	↓	15	15	15.934 P1 15.383	103	106 P1 103
4								

Comments: Refer to Continuing Calibration findings worksheet for list of qualifications and associated samples when reported results do not agree within 10.0% of the recalculated results.

LDC #: SL408 AJ

VALIDATION FINDINGS WORKSHEET
Continuing Calibration Results Verification

Page: 1 of 1
Reviewer: FT

METHOD: GC HPLC

The percent difference (%D) of the initial calibration average Calibration Factors (CF) and the continuing calibration CF were recalculated for the compounds identified below using the following calculation:

% Difference = $100 * (\text{ave. CF} - \text{CF}) / \text{ave. CF}$

Where: ave. CF = initial calibration average CF
CF = continuing calibration CF
A = Area of compound
C = Concentration of compound

#	Standard ID	Calibration Date	Compound	Average CF(ICAL)/ CCV Conc.	Reported	Recalculated	Reported	Recalculated
					CF/ Conc. CCV	CF/ Conc. CCV	%D	%D
1	ceV - 08r 1338	10/14/21	DRO (c ₁₀ -c ₂₄)	15	16	16.8227 F7 16.207	108	112 108
2	ceV - 21r 1127	10/14/21	↓	15	16	16.169 F7 15.562	104	108 104 F
3								
4								

Comments: Refer to Continuing Calibration findings worksheet for list of qualifications and associated samples when reported results do not agree within 10.0% of the recalculated results.

LDC #: 52408 AJ

VALIDATION FINDINGS WORKSHEET Surrogate Results Verification

Page: 1 of 1
Reviewer: FT

METHOD: GC HPLC

The percent recoveries (%R) of surrogates were recalculated for the compounds identified below using the following calculation:

% Recovery: SF/SS * 100

Where: SF = Surrogate Found
SS = Surrogate Spiked

Sample ID: #3

Surrogate	Column/Detector	Surrogate Spiked	Surrogate Found	Percent Recovery	Percent Recovery	Percent Difference
				Reported	Recalculated	
o-Terphenyl		0.19	0.155	80.0	81.578	1.97
					81.578	

Sample ID: _____

Surrogate	Column/Detector	Surrogate Spiked	Surrogate Found	Percent Recovery	Percent Recovery	Percent Difference
				Reported	Recalculated	

	Surrogate Compound		Surrogate Compound		Surrogate Compound		Surrogate Compound		Surrogate Compound
A	Chlorobenzene (CBZ)	G	Octacosane	M	Benzo(e)Pyrene	S	1-Chloro-3-Nitrobenzene	Y	Tetrachloro-m- xylene
B	4-Bromofluorobenzene (BFB)	H	Ortho-Terphenyl	N	Terphenyl-D14	T	3,4-Dinitrotoluene	Z	2-Bromonaphthalene
C	a,a,a-Trifluorotoluene	I	Fluorobenzene (FBZ)	O	Decachlorobiphenyl (DCB)	U	Triphenyltin	AA	Chloro-octadecane
D	Bromochlorobenzene	J	n-Triacontane	P	1-methylnaphthalene	V	Tri-n-propyltin	BB	2,4-Dichlorophenylacetic acid
E	1,4-Dichlorobutane	K	Hexacosane	Q	Dichlorophenyl Acetic Acid (DCAA)	W	Tributyl Phosphate	CC	2,5-Dibromotoluene
F	1,4-Difluorobenzene (DFB)	L	Bromobenzene	R	4-Nitrophenol	X	Triphenyl Phosphate		

LDC #: 52408 AV

VALIDATION FINDINGS WORKSHEET
Matrix Spike/Matrix Spike Duplicates Results Verification

Page: 1 of 1
Reviewer: FT

METHOD: GC HPLC

The percent recoveries (%R) and relative percent differences (RPD) of the matrix spike and matrix spike duplicate were recalculated for the compounds identified below using the following calculation:

$\% \text{Recovery} = 100 * (\text{SSC} - \text{SC}) / \text{SA}$

Where

SSC = Spiked sample concentration

MS = Matrix spike

SC = Sample concentration

MSD = Matrix spike duplicate

$\text{RPD} = \frac{(|\text{SSCMS} - \text{SSCMSD}| * 2)}{(\text{SSCMS} + \text{SSCMSD})} * 100$

SA = Spike added

MS/MSD samples: 15 + 16

Compound	Spike Added (mg/L)		Sample Conc. (mg/L)	Spike Sample Concentration (mg/L)		Matrix spike		Matrix Spike Duplicate		MS/MSD	
	MS	MSD		MS	MSD	Percent Recovery		Percent Recovery		RPD	
						Reported	Recalc.	Reported	Recalc.	Reported	Recalc.
<u>DRD (ep-ent)</u>	<u>28</u>	<u>28</u>	<u>0.49</u>	<u>31</u>	<u>31</u>	<u>108</u>	<u>109</u>	<u>107</u>	<u>109</u>	<u>0.4</u>	<u>0.35</u>
				<u>31.135</u>	<u>31.025</u>						

Comments: Refer to Matrix Spike/Matrix Spike Duplicates findings worksheet for list of qualifications and associated samples when reported results do not agree within 10.0% of the recalculated results.

LDC #: 52408AY

VALIDATION FINDINGS WORKSHEET

Laboratory Control Sample/Laboratory Control Sample Duplicates Results Verification

Reviewer: FT

METHOD: GC HPLC

The percent recoveries (%R) and relative percent differences (RPD) of the laboratory control sample and laboratory control sample duplicate were recalculated for the compounds identified below using the following calculation:

$$\% \text{Recovery} = 100 * (\text{SSC}/\text{SA})$$

$$\text{RPD} = ((\text{SSCLCS} - \text{SSCLCSD}) * 2) / (\text{SSCLCS} + \text{SSCLCSD}) * 100$$

Where SSC = Spiked sample concentration
LCS = Laboratory Control Sample

SA = Spike added
LCSD = Laboratory Control Sample duplicate

LCS/LCSD samples: 125 - 160178

Compound	Spike Added (mg/L)		Spike Sample Concentration (mg/L)		LCS		LCSD		LCS/LCSD	
	LCS	LCSD	LCS	LCSD	Percent Recovery		Percent Recovery		RPD	
					Reported	Recalc.	Reported	Recalc.	Reported	Recalc.
DRG 910-c24	15	NA	14	(14.08)	94.0	94				

Comments: Refer to Laboratory Control Sample/Laboratory Control Sample Duplicate findings worksheet for list of qualifications and associated samples when reported results do not agree within 10.0% of the recalculated results.

LDC #: 52408AY

VALIDATION FINDINGS WORKSHEET Sample Calculation Verification

Page: 1 of 1
Reviewer: FT

METHOD: GC HPLC

C
Y/N/N/A
Y/N/N/A

Were all reported results recalculated and verified for all level IV samples?

Were all recalculated results for detected target compounds within 10% of the reported results?

$$\text{Concentration} = \frac{(A)(F_v)(D_f)}{(RF)(V_s \text{ or } W_s)(\%S/100)}$$

Example:

Sample ID: #2 Compound Name DRO (C10-C24)

A= Area or height of the compound to be measured

Fv= Final Volume of extract

Df= Dilution Factor

RF= Average response factor of the compound
in the initial calibration

Vs= Initial volume of the sample

Ws= Initial weight of the sample

%S= Percent Solid

$$\text{Concentration} = \frac{9.782638 \times 10^7 (1)}{29457.83 (1055)} = 3.147 \text{ mg/L}$$

#	Sample ID	Compound	Reported Concentrations (mg/L)	Recalculated Results Concentrations (mg/L)	Qualifications
	# 2	DRO (C10-C24)	3.1	3.1	

Comments: _____
